JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Douglas, J. F.
Right arrow Articles by Berger, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Douglas, J. F.
Right arrow Articles by Berger, F. M.
Journal of Pharmacology And Experimental Therapeutics, Vol. 136, Issue 1, 5-9, 1962
Copyright © 1962 by American Society for Pharmacology and Experimental Therapeutics

THE METABOLIC FATE OF MEBUTAMATE (CAPLA)

J. F. Douglas 1, B. J. Ludwig 1, T. Ginsberg 1, and F. M. Berger 1

1 Wallace Laboratories, Cranbury, New Jersey

Mebutamate is absorbed rapidly into the bloodstream of man, reaching a peak concentration between the first and second hours after oral administration.

The metabolism of mebutamate leads to at least three urinary end-products: unchanged drug present in small quantities, a hydroxylated derivative, 2-methyl-2-(beta-hydroxyl-agr-methylpropyl)-1,3-propanediol dicarbamate, which is the primary metabolite and a glucuronide conjugate.

Submitted on September 15, 1961






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1962 by the American Society for Pharmacology and Experimental Therapeutics.